SCHEMBL18790990

SCHEMBL18790990

CC(C)NC(=O)CN1CCN(c2cncc(Cl)n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ CYP11B2 P19099 4/20 0.49
▸ UGT8 Q16880 3/20 0.47
▸ PTPN11 Q06124 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ HTR2C P28335 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ CHRM5 P08912 1/20 0.45
▸ CHRM3 P20309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18790702 0.77 CYP11B2 (0.52) ALDH1A1KDM4ESMN1; SMN2TDP1CYP11B2
SCHEMBL10294633 0.75 HTR2A (0.60) ALDH1A1KDM4EMEN1CYP1A2CYP3A4
SCHEMBL18791085 0.75 CYP11B2 (0.73) ALDH1A1KDM4ESMN1; SMN2TDP1CYP11B2
SCHEMBL18790696 0.74 CYP11B2 (0.61) CYP11B2UGT8CYP11B1
SCHEMBL3365732 0.73 HTR2A (0.54) ALDH1A1KDM4EMEN1CYP1A2CYP3A4
SCHEMBL23464917 0.73 CHRM5 (0.75) ALDH1A1KDM4ESMN1; SMN2TDP1MEN1
SCHEMBL18791083 0.73 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2TDP1CYP11B2
SCHEMBL22236774 0.73 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2TDP1CYP11B2
SCHEMBL12813911 0.73 HTR2A (0.57) ALDH1A1KDM4EMEN1CYP1A2CYP3A4
SCHEMBL18790991 0.72 CYP11B2 (0.90) ALDH1A1KDM4ESMN1; SMN2TDP1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3381904-B1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-07-28 — — EP disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 — — US disclosed
WO-2017069226-A1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound REN, NR3C2, NR5A1 ALDH1A1 1495/4885KDM4E 2819/4885SMN1; SMN2 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback